Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology

Journal of Neurochemistry

Volumn 128, Issue 4, 2014, Pages 577-591

  Liu, Shan ^a   Breitbart, Ariel ^a   Sun, Yanjie ^a   Mehta, Pankaj D ^b   Boutajangout, Allal ^a,c   Scholtzova, Henrieta ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Amyloid ; apolipoprotein E; behavior; histochemistry; tau

Indexed keywords

ALZHEIMER'S DISEASE; AMYLOID Β; APOLIPOPROTEIN E; BEHAVIOR; HISTOCHEMISTRY; TAU;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEINS E; BLOTTING, WESTERN; BRAIN CHEMISTRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GLIOSIS; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; POSTURAL BALANCE; TAU PROTEINS;

EID: 84893874165     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12484     Document Type: Article

References (67)

1. Asuni A., Boutajangout A., Scholtzova H., Knudsen E., Li Y., Quartermain D., Frangione B., Wisniewski T., and, Sigurdsson E. M., (2006) Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur. J. Neurosci. 24, 2530-2542. (Pubitemid 44726765)
2. Asuni A. A., Boutajangout A., Quartermain D., and, Sigurdsson E. M., (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129. (Pubitemid 47312068)
3. Batsch N. L., and, Mittelman M. S., (2012) World Alzheimer Report 2012. Alzheimer's Disease International.
4. Bitan G., Kirkitadze M. D., Lomakin A., Vollers S. S., Benedek G. B., and, Teplow D. B., (2003) Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Nat. Acad. Sci. USA 100, 330-335. (Pubitemid 36078074)
5. Boutajangout A., Ingadottir J., Davies P., and, Sigurdsson E. M., (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118, 658-667.
6. Brecht W. J., Harris F. M., Chang S., et al,. (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527-2534. (Pubitemid 38327965)
7. Bu G., (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344.
8. Castellano J. M., Kim J., Stewart F. R., et al,. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57.
9. Chang S., Ma T. R., Miranda R. D., Balestra M. E., Mahley R. W., and, Huang Y., (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl Acad. Sci. USA 102, 18694-18699. (Pubitemid 43011288)
10. C monoclonal antibody infusion as a novel treatment for Aβ oligomer cognitive cognitive deficits. BMC Neuroscience 11, 130.
11. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., and, Ashe K. H., (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84. (Pubitemid 41236735)
12. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M. B., Holtzman D. M., and, Zlokovic B. V., (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013.
13. Fleming L. M., Weisgraber K. H., Strittmatter W. J., Troncoso J. C., and, Johnson G. V., (1996) Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. Exp. Neurol. 138, 252-260. (Pubitemid 26135201)
14. Fukumoto H., Tokuda T., Kasai T., Ishigami N., Hidaka H., Kondo M., Allsop D., and, Nakagawa M., (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716-2726.
15. Golabek A. A., Soto C., Vogel T., and, Wisniewski T., (1996) The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J. Biol. Chem. 271, 10602-10606.
16. Goni F., Prelli F., Ji Y., et al,. (2010) Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS ONE 5, e13391.
17. Han S. H., Hulette C., Saunders A. M., Einstein G., Pericak-Vance M., Strittmatter W. J., Roses A. D., and, Schmechel D. E., (1994) Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp. Neurol. 128, 13-26. (Pubitemid 24278361)
18. Hao J., Zhang W., Zhang P., Liu R., Liu L., Lei G., Su C., Miao J., and, Li Z., (2010) Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro. Neuropeptides 44, 305-313.
19. Hardy J., (2006) Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers. Dis. 9, 151-153. (Pubitemid 44253307)
20. Hauser P. S., Narayanaswami V., and, Ryan R. O., (2011) Apolipoprotein E: from lipid transport to neurobiology. Prog. Lipid Res. 50, 62-74.
21. Holtzman D. M., Mandelkow E., and, Selkoe D. J., (2012) Alzheimer disease in 2020. Cold Spring Harb. Perspect. Med. 2, a011585.
22. Huang Y., (2011) Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models. Biochem. Soc. Trans. 39, 924-932.
23. Kim K. S., Wen G. Y., Bancher C., Chen C. M. J., Sapienza V., Hong H., and, Wisniewski H. M., (1990) Detection and quantification of amyloid β-peptide with 2 monoclonal antibodies. Neurosci. Res. Comm. 7, 113-122.
24. Klybin I., Betts V., Blennow K., et al,. (2008) Aβ dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28, 4231-4237.
25. Koffie R. M., Hashimoto T., Tai H. C., et al,. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135, 2155-2168.
26. Kuszczyk M. A., Sanchez S., Pankiewicz J., Kim J., Duszczyk M., Guridi M., Asuni A. A., Sullivan P. M., Holtzman D. M., and, Sadowski M. J., (2013) Blocking the interaction between apolipoprotein E and Abeta reduces intraneuronal accumulation of Abeta and inhibits synaptic degeneration. Am. J. Pathol. 182, 1750-1768.
27. Kutner K. C., Erlanger D. M., Tsai J., Jordan B., and, Relkin N. R., (2000) Lower cognitive performance of older football players possessing apolipoprotein E epsilon4. Neurosurgery 47, 651-657.
28. Lemere C. A., and, Masliah E., (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6, 108-119.
29. Leroy A., Landrieu I., Huvent I., Legrand D., Codeville B., Wieruszeski J. M., and, Lippens G., (2010) Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J. Biol. Chem. 285, 33435-33444.
30. Liu Q., Wu W. H., Fang C. L., et al,. (2011) Mapping ApoE/Abeta binding regions to guide inhibitor discovery. Mol. BioSyst. 7, 1693-1700.
31. Liu C. C., Kanekiyo T., Xu H., and, Bu G., (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106-118.
32. Mahley R. W., and, Huang Y., (2009) Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Ann. Neurol. 65, 623-625.
33. Masters C. L., and, Selkoe D. J., (2012) Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006262.
34. Miller G., (2011) Neuropathology. A battle no soldier wants to fight. Science 333, 517-519.
35. Morgan D., Gordon M. N., Tan J., Wilcock D., and, Rojiani A. M., (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 64, 743-753. (Pubitemid 41285806)
36. Nelson P. T., Alafuzoff I., Bigio E. H., et al,. (2012) Correlation of Alzheimer's disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropath. Exp. Neurol. 71, 362-381.
37. Nielsen H. M., Mulder S. D., Belien J. A., Musters R. J., Eikelenboom P., and, Veerhuis R., (2010) Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58, 1235-1246.
38. Oddo S., Caccamo A., Kitazawa M., Tseng B. P., and, LaFerla F. M., (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24, 1063-1070. (Pubitemid 37487883)
39. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., and, LaFerla F. M., (2003b) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. (Pubitemid 36937044)
40. Otvos L., Jr, Feiner L., Lang E., Szendrei G. I., Goedert M., and, Lee V. M., (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669-673.
41. Panza F., Frisardi V., Solfrizzi V., Imbimbo B. P., Logroscino G., Santamato A., Greco A., Seripa D., and, Pilotto A., (2012) Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 4, 213-238.
42. Permanne B., Perez C., Soto C., Frangione B., and, Wisniewski T., (1997) Detection of apolipoprotein E dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem. Biophys. Res. Commun. 240, 715-720. (Pubitemid 28271784)
43. Potter H., and, Wisniewski T., (2012) Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. Int. J. Alz. Dis. 2012, 489428.
44. Roher A. E., Cribbs D. H., Kim R. C., et al,. (2013) Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS ONE 8, e59735.
45. Rubenstein R., Chang B., Gray P., Piltch M., Bulgin M. S., Sorensen-Melson S., and, Miller M. W., (2011) Prion disease detection, PMCA kinetics, and IgG in urine from sheep naturally/experimentally infected with scrapie and deer with preclinical/clinical chronic wasting disease. J. Virol. 85, 9031-9038.
46. Sadowski M., Pankiewicz J., Scholtzova H., et al,. (2004) Blocking the apolipoprotein E/ß-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am. J. Pathol. 165, 937-948. (Pubitemid 39129300)
47. Sadowski M., Pankiewicz J., Scholtzova H., Mehta P., Prelli F., Quartermain D., and, Wisniewski T., (2006) Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc. Natl Acad. Sci. USA 103, 18787-18792.
48. Schmidt S. D., Jiang Y., Nixon R. A., and, Mathews P. M., (2005) Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol. Biol. 299, 267-278.
49. Scholtzova H., Kascsak R. J., Bates K. A., Boutajangout A., Kerr D. J., Meeker H. C., Mehta P. D., Spinner D. S., and, Wisniewski T., (2009) Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J. Neurosci. 29, 1846-1854.
50. Stougaard M., Juul S., Andersen F. F., and, Knudsen B. R., (2011) Strategies for highly sensitive biomarker detection by Rolling Circle Amplification of signals from nucleic acid composed sensors. Integr. Biol. (Camb.) 3, 982-992.
51. Strittmatter W. J., Weisgraber K. H., Goedert M., et al,. (1994) Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125, 163-171. (Pubitemid 24076094)
52. Tai L. M., Bilousova T., Jungbauer L., et al,. (2013) Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J. Biol. Chem. 288, 5914-5926.
53. Tesseur I., van D. J., Spittaels K., Van den Haute C., Moechars D., and, Van L. F., (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156, 951-964. (Pubitemid 30626953)
54. Upadhaya A. R., Lungrin I., Yamaguchi H., Fandrich M., and, Thal D. R., (2012) High-molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J. Cell Mol. Med. 16, 287-295.
55. Van Vickle G. D., Esh C. L., Daugs I. D., et al,. (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am. J. Pathol. 173, 483-493.
56. Verghese P. B., Castellano J. M., and, Holtzman D. M., (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10, 241-252.
57. Wadghiri Y. Z., Li J., Hoang D. M., Sun Y., Xu H., Tsui W., Li Y., Wang A., de Leon M., and, Wisniewski T., (2013) Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS ONE 8, e57097.
58. Watt A. D., Perez K. A., Rembach A., et al,. (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol. 125, 549-564.
59. Wisniewski T., (2012) Active immunotherapy for Alzheimer's disease. Lancet Neurol. 11, 571-572.
60. Wisniewski T., and, Boutajangout A., (2010) Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct. Funct. 214, 201-218.
61. Wisniewski T., and, Goni F., (2013) Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins., USA.
62. Wisniewski T., and, Sadowski M., (2008) Preventing Aβ fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors. BMC Neuroscience 9, 1-5.
63. Wisniewski T., Castaño E. M., Golabek A. A., Vogel T., and, Frangione B., (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030-1035. (Pubitemid 24345650)
64. Wyss-Coray T., and, Rogers J., (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346.
65. Xu F., Grande A. M., Robinson J. K., Previti M. L., Vasek M., Davis J., and, van Nostrand W. E., (2007) Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 146, 98-107. (Pubitemid 46654629)
66. Yang J., Ji Y., Mehta P., Bates K. A., Sun Y., and, Wisniewski T., (2011) Blocking the apolipoprotein E/amyloid β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J. Alzheimers. Dis. 24, 269-285.
67. Zahs K. R., and, Ashe K. H., (2010) 'Too much good news'-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 33, 381-389.